PDCD1 and metastatic malignant neoplasm in the lymph nodes: In patients receiving neoadjuvant anti-programmed cell death-1 (PD-1) immunotherapy by pembrolizumab, the sensitivity and specificity of PET/CT to predict lymph node metastasis was investigated before and after treatment (27).